Sanofi India's Financial Results Show Mixed Performance, Receives 'Sell' Call from MarketsMOJO

Sanofi India, a midcap pharmaceutical company, has recently declared its financial results for the quarter ending September 2024. The company has received a 'Sell' call from MarketsMOJO, indicating a negative outlook for its stock.

According to the financials, Sanofi India has seen a decline in its profit after tax (PAT) by 25.5% compared to the average of the previous four quarters. This has resulted in a negative trend for the company's near-term PAT. However, the profit before tax (PBT) has shown a growth of 28.3% in the same period, indicating a positive trend for the near future.

One of the factors contributing to the negative trend in PAT is the company's debtors turnover ratio, which has been consistently falling in the last five half-yearly periods. This indicates a slower pace in settling its debtors, affecting the company's profitability.

Moreover, the earnings per share (EPS) for Sanofi India has also declined in the last five quarters, indicating a lower profitability for its shareholders. The company's cash and cash equivalents have also decreased in the last six half-yearly periods, affecting its short-term liquidity.

Despite these challenges, Sanofi India has shown some positive aspects in its financials, such as a growth in PBT and a positive trend in near-term PBT. However, investors should carefully consider all the factors before making any investment decisions.